News & Events
Report from regional patient meeting in Sarajevo, Bosnia & Herzegovina
20 April 2013
Gaucher patients, their families and doctors from Slovenia, Croatia, Bosnia & Herzegovina, Serbia, Montenegro and Macedonia met in Sarajevo, from 5th-7th April 2013.
The second regional meeting of Gaucher patients and The first regional meeting …Austrian Gaucher Meeting 21/23.09 (Innsbruck)
18 April 2013
The Austrian Gaucher Association Meeting will take place on 20/21 September 2013 in Innsbruck, Austria.
Please contact Roman Pichler for more details: pichler@liwest.at5th Nordic-Baltic Gaucher Meeting 19-21.4 in Talinn (Estonia)
27 March 2013
More than 85 patients and relative have signed up for the 5th Nordic-Baltic Gaucher Meeting, making this meeting the largest ever.
Patients from Norway, Sweden, Denmark, Finland, Lithuania, Latvia and Estonia are meeting for a two day seminar with …Canada to join the EGA
26 March 2013
-
We are pleased to announce that The National Gaucher Foundation of Canada has joined the EGA as an associate member.
-
Bosnia and Herzegovina: The second regional patient meeting
28 January 2013
The second regional patient meeting will take place in Sarajevo (Bosnia and Herzegovina), 5.-7. 4. 2013.
Gaucher patients and physicians from Slovenia, Croatia, Bosnia and Herzegovina, Serbia, Montenegro, Kosovo and Macedonia are invited. Welcome …
Alert for Gaucher Patients and Families regarding Zavesca Getz Product
14 December 2012
The EGA has been alerted to the existence of another pharmaceutical product called Zavesca that is causing some confusion amongst Gaucher patients throughout the world. The product, whose packaging is almost identical to that of the genuine …
EC denies Taliglucerase (Elelyso) market approval for Type 1 GD
6 November 2012
European Commission denies Taliglucerase (Elelyso) market approval for Type 1 Gaucher Disease
On 3 July 2012, the Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of a marketing authorisation for the medicinal product …
Genzyme Phase 3 Study of Eliglustat Meets Primary Endpoint
18 October 2012
Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for GD Meets Primary Endpoint
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that ENGAGE, the first Phase 3 trial of its …
Market approval of Elelyso by the Israeli Ministry of Health
3 October 2012
Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli Ministry of Health
CARMIEL, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) …
India to join the EGA
27 September 2012
We are pleased to announce that the LSD Support Society of India has joined the EGA as an associate member.